Prospective Grant of Exclusive Patent License: Novel Therapeutics for the Treatment of Neurodegenerative Disorders, 8440-8441 [2023-02772]
Download as PDF
<![CDATA[
8440
Federal Register / Vol. 88, No. 27 / Thursday, February 9, 2023 / Notices
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Vaccine Adjuvant
Development Program in Infectious and
Immune-Mediated Diseases (N01).
Date: March 6–8, 2023.
Time: 11:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G45,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Vanitha S. Raman, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G45, Rockville, MD
20852, 301–761–7949, vanitha.raman@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: February 6, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–02794 Filed 2–8–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
khammond on DSKJM1Z7X2PROD with NOTICES
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
VerDate Sep<11>2014
16:28 Feb 08, 2023
Jkt 259001
Emphasis Panel; Understanding Persistent
Signs and Symptoms Attributed to Posttreatment Lyme Disease (R01 Clinical Trial
Not Allowed).
Date: March 14, 2023.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F21B,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Maryam Feili-Hariri,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F21B,
Rockville, MD 20852, 240–669–5026,
haririmf@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: February 6, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–02795 Filed 2–8–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Alcohol Abuse
and Alcoholism; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel; NRSA Individual
Fellowship (F30, F31, F32) Review Panel.
Date: February 22, 2023.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Alcohol Abuse and
Alcoholism, 6700B Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Luis Espinoza, Ph.D.,
Scientific Review Officer, Extramural Project
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
Review Branch, Office of Extramural
Activities, National Institute on Alcohol
Abuse and Alcoholism, 6700B Rockledge
Drive, Room 2109, Bethesda, MD 20892,
(301) 443–8599, espinozala@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel; NIAAA Special Emphasis
Panel for Member Conflict Applications.
Date: April 11, 2023.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Alcohol Abuse and
Alcoholism, 6700B Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Luis Espinoza, Ph.D.,
Scientific Review Officer, Extramural Project
Review Branch, Office of Extramural
Activities, National Institute on Alcohol
Abuse and Alcoholism, 6700B Rockledge
Drive, Room 2109, Bethesda, MD 20892,
(301) 443–8599, espinozala@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants;
93.701, ARRA Related Biomedical Research
and Research Support Awards, National
Institutes of Health, HHS)
Dated: February 6, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–02805 Filed 2–8–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: Novel Therapeutics for the
Treatment of Neurodegenerative
Disorders
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institute of
Neurological Disorders and Stroke
(‘‘NINDS’’), an institute of the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive,
sublicensable patent license to
University College London Business,
Ltd. (‘‘UCLB’’), incorporated in England
and Wales under company registration
number 02776963 whose registered
office address is University College
SUMMARY:
E:\FR\FM\09FEN1.SGM
09FEN1
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 88, No. 27 / Thursday, February 9, 2023 / Notices
London, Gower Street, London WC1E
6BT, United Kingdom, for NINDS’s
rights to the patent applications listed in
the Supplementary Information section
of this notice. UCLB is the technology
transfer company of the University
College London (‘‘UCL’’), a non-profit
research institution located in London,
United Kingdom.
DATES: Only written comments and/or
applications for a license which are
received by the National Institute of
Neurological Disorders and Stroke
Technology Transer Office by February
24, 2023 will be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
exclusive patent license should be
directed to: Lola Olufemi, Ph.D., Senior
Technology Portfolio Manager; NINDS
Technology Transfer Office, at
Telephone: (301) 451–3748 or Email:
olufemioo@nih.gov.
SUPPLEMENTARY INFORMATION: The
following and all continuing U.S. and
foreign patents/patent applications
thereof are the intellectual properties to
be licensed under the prospective
agreement to UCLB include: PCT patent
application number PCT/EP2021/
084908, entitled ‘‘Novel Therapeutics
for the treatment of neurodegenerative
disorders’’ (claiming priority to GB
2019418.9, filed December 9, 2020) filed
December 9, 2021 (HHS Reference E–
198–2021) and GB patent application
number 2117758.9, entitled,
‘‘Therapeutics for the treatment of
neurodegenerative disorders’’ (HHS
Reference E–071–2023), filed December
9, 2021.
With respect to the inventions
described and claimed in the patent
applications PCT/EP2021/084908 and
GB 2117758.9, each of the inventors has
assigned their rights to their respective
employers or an entity which manages
the intellectual property for their
employer (The United States of
America, UCL and UCLB). The
prospective license will be for the
purpose of consolidating the patent
rights with UCLB, the co-owner of said
rights, for commercial development and
marketing. Consolidation of these coowned rights is intended to expedite
development of the invention,
consistent with the goals of the BayhDole Act codified as 35 U.S.C. 200–212.
The prospective patent license will be
worldwide, exclusive, and may be
limited to those fields of use
commensurate in scope with the patent
rights. It will be sublicensable, and any
sublicenses granted by UCLB will be
subject to the provisions of 37 CFR part
404.
VerDate Sep<11>2014
16:28 Feb 08, 2023
Jkt 259001
The technologies describe antisense
oligonucleotides (ASOs) that are capable
of modulating splicing by preventing
inclusion of an UNC13A cryptic exon
into an UNC13A mature mRNA. Guide
RNAs including the ASO, and viral
vectors expressing the ASO are also
described. Such ASOs and guide RNAs
may be used as a medicament, for
example, to treat neurodegenerative
disorders, particularly those associated
with TDP–43 pathology.
This notice is made pursuant to 35
U.S.C. 209 and 37 CFR part 404. The
prospective exclusive patent license
will include terms for the sharing of
royalty income with NINDS from
commercial sublicenses of the patent
rights and may be granted unless within
fifteen (15) days from the date of this
published notice the NINDS receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license
that are timely filed in response to this
notice will be treated as objections to
the grant of the contemplated exclusive
patent license. In response to this
Notice, the public may file comments or
objections. Comments and objections,
other than those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information from these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C
552.
Susan E Ano,
Branch Chief, Technology Transfer Branch,
National Institute of Neurological Disorders
and Stroke.
[FR Doc. 2023–02772 Filed 2–8–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
8441
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Musculoskeletal, Rehabilitation
and Skin Sciences.
Date: March 8–9, 2023.
Time: 9:00 a.m. to 10:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Carmen Bertoni, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 805B,
Bethesda, MD 20892, (301) 867–5309,
bertonic2@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cell Biology and Development of
Eye.
Date: March 8, 2023.
Time: 1:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Rass M Shayiq, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2182,
MSC 7818, Bethesda, MD 20892, (301) 435–
2359, shayiqr@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Sensory and Motor
Neurosciences, Cognition and Perception.
Date: March 9–10, 2023
Time: 8:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Bethesdan Hotel, 8120
Wisconsin Ave, Bethesda, MD 20814.
Contact Person: John N Stabley, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 594–0566, stableyjn@
csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Oncology.
Date: March 9–10, 2023.
Time: 8:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, Montgomery County
Conference Center Facility, 5701 Marinelli
Road, North Bethesda, MD 20852.
Contact Person: Reigh-Yi Lin, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
E:\FR\FM\09FEN1.SGM
09FEN1
]]>Agencies
[Federal Register Volume 88, Number 27 (Thursday, February 9, 2023)]
[Notices]
[Pages 8440-8441]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-02772]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: Novel Therapeutics
for the Treatment of Neurodegenerative Disorders
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Neurological Disorders and Stroke
(``NINDS''), an institute of the National Institutes of Health,
Department of Health and Human Services, is contemplating the grant of
an exclusive, sublicensable patent license to University College London
Business, Ltd. (``UCLB''), incorporated in England and Wales under
company registration number 02776963 whose registered office address is
University College
[[Page 8441]]
London, Gower Street, London WC1E 6BT, United Kingdom, for NINDS's
rights to the patent applications listed in the Supplementary
Information section of this notice. UCLB is the technology transfer
company of the University College London (``UCL''), a non-profit
research institution located in London, United Kingdom.
DATES: Only written comments and/or applications for a license which
are received by the National Institute of Neurological Disorders and
Stroke Technology Transer Office by February 24, 2023 will be
considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated exclusive patent license
should be directed to: Lola Olufemi, Ph.D., Senior Technology Portfolio
Manager; NINDS Technology Transfer Office, at Telephone: (301) 451-3748
or Email: [email protected].
SUPPLEMENTARY INFORMATION: The following and all continuing U.S. and
foreign patents/patent applications thereof are the intellectual
properties to be licensed under the prospective agreement to UCLB
include: PCT patent application number PCT/EP2021/084908, entitled
``Novel Therapeutics for the treatment of neurodegenerative disorders''
(claiming priority to GB 2019418.9, filed December 9, 2020) filed
December 9, 2021 (HHS Reference E-198-2021) and GB patent application
number 2117758.9, entitled, ``Therapeutics for the treatment of
neurodegenerative disorders'' (HHS Reference E-071-2023), filed
December 9, 2021.
With respect to the inventions described and claimed in the patent
applications PCT/EP2021/084908 and GB 2117758.9, each of the inventors
has assigned their rights to their respective employers or an entity
which manages the intellectual property for their employer (The United
States of America, UCL and UCLB). The prospective license will be for
the purpose of consolidating the patent rights with UCLB, the co-owner
of said rights, for commercial development and marketing. Consolidation
of these co-owned rights is intended to expedite development of the
invention, consistent with the goals of the Bayh-Dole Act codified as
35 U.S.C. 200-212.
The prospective patent license will be worldwide, exclusive, and
may be limited to those fields of use commensurate in scope with the
patent rights. It will be sublicensable, and any sublicenses granted by
UCLB will be subject to the provisions of 37 CFR part 404.
The technologies describe antisense oligonucleotides (ASOs) that
are capable of modulating splicing by preventing inclusion of an UNC13A
cryptic exon into an UNC13A mature mRNA. Guide RNAs including the ASO,
and viral vectors expressing the ASO are also described. Such ASOs and
guide RNAs may be used as a medicament, for example, to treat
neurodegenerative disorders, particularly those associated with TDP-43
pathology.
This notice is made pursuant to 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive patent license will include terms for the
sharing of royalty income with NINDS from commercial sublicenses of the
patent rights and may be granted unless within fifteen (15) days from
the date of this published notice the NINDS receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part
404.
Complete applications for a license that are timely filed in
response to this notice will be treated as objections to the grant of
the contemplated exclusive patent license. In response to this Notice,
the public may file comments or objections. Comments and objections,
other than those in the form of a license application, will not be
treated confidentially, and may be made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information from these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C 552.
Susan E Ano,
Branch Chief, Technology Transfer Branch, National Institute of
Neurological Disorders and Stroke.
[FR Doc. 2023-02772 Filed 2-8-23; 8:45 am]
BILLING CODE 4140-01-P
